logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Mantle Cell Lymphoma

    FiltersReset Filters
    13 results

    • bortezomib

      (Bortezomib)
      Ingenus Pharmaceuticals, LLC
      Usage: Bortezomib for Injection is indicated for the treatment of adult patients with multiple myeloma and mantle cell lymphoma.

    • bortezomib

      (Bortezomib)
      Novadoz Pharmaceuticals LLC
      Usage: Bortezomib for injection is indicated for the treatment of adult patients with multiple myeloma and mantle cell lymphoma.

    • bortezomib

      (BORTEZOMIB)
      Hospira, Inc.
      Usage: Bortezomib for Injection is indicated for the treatment of adult patients with multiple myeloma and mantle cell lymphoma.

    • bortezomib

      (bortezomib)
      Hikma Pharmaceuticals USA Inc.
      Usage: Bortezomib for injection is indicated for the treatment of adult patients with multiple myeloma and mantle cell lymphoma.

    • bortezomib

      (Bortezomib)
      NorthStar RxLLC
      Usage: Bortezomib for injection is indicated for the treatment of adult patients with multiple myeloma and mantle cell lymphoma.

    • boruzu

      (Bortezomib)
      Amneal Pharmaceuticals LLC
      Usage: BORUZU is indicated for the treatment of adult patients with multiple myeloma and mantle cell lymphoma.

    • brukinsa

      (zanubrutinib)
      BEIGENE USA, INC.
      Usage: BRUKINSA is indicated for treating adult patients with mantle cell lymphoma, Waldenström's macroglobulinemia, relapsed or refractory marginal zone lymphoma, chronic lymphocytic leukemia or small lymphocytic lymphoma, and relapsed or refractory follicular lymphoma in combination with obinutuzumab, after prior therapies.

    • calquence

      (acalabrutinib)
      AstraZeneca Pharmaceuticals LP
      Usage: CALQUENCE is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous stem cell transplantation, previously treated MCL patients, and those with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

    • jaypirca

      (pirtobrutinib)
      Eli Lilly and Company
      Usage: JAYPIRCA® is indicated for adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two systemic therapies, including a BTK inhibitor. It is also indicated for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after two prior therapies, including a BTK and a BCL-2 inhibitor.

    • lenalidomide

      (Lenalidomide)
      Biocon Pharma Inc.
      Usage: Lenalidomide is indicated for treating multiple myeloma (MM) in combination with dexamethasone, as maintenance therapy post-autologous stem cell transplantation, and for transfusion-dependent anemia due to myelodysplastic syndromes. It's also used for relapsed mantle cell lymphoma and in combination with rituximab for follicular and marginal zone lymphomas.